Pharma Pricing and Market Access 2019 Day 1

08:30

Registration & refreshments

Wendy Jory
08:55

Chair’s opening remarks

Wendy Jory, Head of Global Pricing and Contracting Strategies, GlaxoSmithKline
09:20

TBC

Luc Boileau
10:00

What is going on in Quebec about Market Access?

  • Examining Quebec life sciences strategy: Integration of medicines and technological innovations
  • Achieving cost reduction and improving access to medicines
  • Re-editing the evaluation process for the introduction of innovative medication and technologies
10:20

Speed Networking

10:40

Morning Refreshments

Andreia Ribeiro
11:20

Biosimilar pricing and access expectations in Europe

Ryan Saadi
11:40

The admission of value in the new marketplace

Ryan Saadi, VP, Global Market Access, CSL Behring
round tables
12:00

25 Roundtables (max 15 PAX)

Room At The Top? The Case For a Chief Value Officer and The Three Pillars of Responsibility: Value Communication, Value Creation and Value Governance
Don Creighton

Don Creighton, Managing Director, Life Sciences Practice, Huron

Roundtable 10: Sustainable pricing models for orphan drugs
Ajan Reginald

Ajan Reginald, Chief Executive Officer, Celixir

Roundtable 11: Accelerating access to treatments for rare diseases
Elizabeth Owen

Elizabeth Owen, Head Of Translational Research Development, The Muscular Dystrophy U.K.

Roundtable 15: Pricing Strategy – What to Do and When?
Andreia Ribeiro

Andreia Ribeiro, Engagement Manager, Lifescience Dynamics Ltd

Roundtable 1: Bridging the gap between clinical development and medical affairs, tailoring clinical trials to meet both MA and HTA requirements
Roundtable 2: Developments in pricing and access for biosimilars in Europe
Cristina Martin-Rinconada

Cristina Martin-Rinconada, Associate Director Strategic Pricing, Biogen Biosimilars Europe

Roundtable 3: Examining emerging trends for market access in LMICs, opportunities and challenges
JUAN CASTANO

JUAN CASTANO, Lawyer health regulation enforceability, Management Science For Health

Roundtable 5: Payer engagement in the world of orphan drugs
Fabrizio Zucca

Fabrizio Zucca, Director Patient Access Dach, Sobi

Roundtable 8: Role of RWE in oncology
Patrick Mollon

Patrick Mollon, Former Director Gheore, Shire

Roundtable 9: Exploring regulatory and market access developments in advanced therapies
Renske Ten Ham

Renske Ten Ham, Phd Candidate, Utrecht University

12:50

Lunch

Evidence

PRICING & MARKET ACCESS

RARE DISEASES

BIG DATA, DIGITAL HEALTH & ANALYTICS

HTA

EMERGING MARKETS

BIOSIMILARS

BIG DATA, DIGITAL HEALTH & ANALYTICS
14:10

Chair’s remarks

PRICING & MARKET ACCESS
14:15

Developments in indication and combination pricing models

  • A look at the reimbursement and pricing environment and challenges for indication-based and combination therapy pricing
  • Addressing the information gap: Infrastructure needs
  • Where are we? Case studies on indication-based and combo pricing
HTA
14:15

Quantifying the ‘patient voice’: the importance of tolerability and quality-of-survival in HTA decisions

  • HTA and payer-relevant quantitative concepts to characterize AE profiles and tolerability will be reviewed
  • HTA acceptance of these quant. approaches will be illustrated and appraised
  • Examples and (potential future) approaches, for HTA and Access success will be discussed
BIOSIMILARS
14:15

Presentation

Evidence
14:35

Sponsor presentation

PRICING & MARKET ACCESS
14:35

The Transaction Pricing Opportunity

Alejandra (Sandra) Garitonandía, Business Development, Vistex
RARE DISEASES
14:35

Sponsor presentation

HTA
14:35

Sponsor presentation

EMERGING MARKETS
14:35

Sponsor presentation

BIOSIMILARS
14:35

Sponsor presentation

HTA
14:55

Title TBC

Florian Turk, Head Of Global Payor Marketing, Sales And Relations, Sandoz
EMERGING MARKETS
14:55

Latest HTA developments in Colombia

Aurelio Mejia, Former Deputy Director Of Hta, IETS
BIOSIMILARS
14:55

Presentation

EVIDENCE

PRICING & MARKET ACCESS

RARE DISEASES

BIG DATA, DIGITAL HEALTH & ANALYTICS

VALUE

EMERGING MARKETS AND SOUTH KOREA

BIOSIMILARS

Evidence
15:15

Chair’s remarks

BIG DATA, DIGITAL HEALTH & ANALYTICS
15:15

Chair’s remarks

VALUE
15:15

Chair’s remarks

Rafaat Rahmani, President, Lifescience Dynamics Ltd
Evidence
15:20

Use of value frameworks within oncology in Europe

  • Innovation and launches in oncology are moving at a rapid pace, potentially resulting in a delay in formal reimbursement appraisal and guidance
  • A number of value frameworks have been developed with the intent of providing rapid advice to oncologists on the clinical benefit of these new drugs
  • These value frameworks have many advantages, including clarity and brevity, but they do not replace the full value assessment of a formal HTA
BIG DATA, DIGITAL HEALTH & ANALYTICS
15:20

4D Insights - powering access

  • Aligning Payers, Policy Markers, Prescribers and Patient Insight using the power of Big Data
  • Real-time Insights giving competitive advantage
  • Measuring impact in real-time from within the health system
BIOSIMILARS
15:20

Presentation

Evidence
15:40

Sponsor presentation

PRICING & MARKET ACCESS
15:40

Sponsor presentation

RARE DISEASES
15:40

Chair’s remarks

BIG DATA, DIGITAL HEALTH & ANALYTICS
15:40

Sponsor presentation

VALUE
15:40

Reserved for Executive Insight

EMERGING MARKETS
15:40

Sponsor presentation

BIOSIMILARS
15:40

Sponsor presentation

RARE DISEASES
16:00

TBC

16:10

Afternoon Refreshment Break

EVIDENCE

REIMBURSEMENT

PRICING & MARKET ACCESS

RARE DISEASES

BIG DATA, DIGITAL HEALTH & ANALYTICS

EMERGING MARKETS

BIOSIMILARS

REIMBURSEMENT
16:50

Chair’s remarks

PRICING & MARKET ACCESS
16:50

Chair’s remarks

RARE DISEASES
16:50

Chair’s remarks

BIG DATA, DIGITAL HEALTH & ANALYTICS
16:50

Chair’s remarks

EMERGING MARKETS
16:50

Chair’s remarks

RARE DISEASES
16:55

Utilising disease registries for orphan drug launch

  • Utilising disease registries is vital in rare diseases and a multicountry, multi-stakeholder approach will be discussed
  • In Europe, linkage is needed as well between registries and EU Reference networks and this can prove to be an invaluable relation ship
  • Technological challenges are a problem and potential approaches will be explored
EMERGING MARKETS
16:55

Presentation

Evidence
17:15

Sponsor presentation

PRICING & MARKET ACCESS
17:15

Sponsor presentation reserved for Eversana

RARE DISEASES
17:15

Sponsor presentation

BIG DATA, DIGITAL HEALTH & ANALYTICS
17:15

Sponsor presentation

EMERGING MARKETS
17:15

Sponsor presentation

BIOSIMILARS
17:15

Sponsor presentation

REIMBURSEMENT
17:35

Reimbursement within the world of Oncology

  • Oncology Environment and Patient Access to the Oncology Therapies
  • Patient Access & Support Programs in Oncology
  • Reimbursement issues and impact of the reimbursement delays in Oncology
EMERGING MARKETS
17:35

Presentation

17:55

Close of congress

last published: 18/Jan/19 15:55 GMT